Aduro Biotech, Inc.

Novartis AG has jumped onto the M&A merry-go-round to pick up Chinook Therapeutics Inc. , paying $3.2bn upfront to get hold of two late-stage drugs for the rare kidney disease IgA nephropathy (IgAN)

Exelixis, Inc. has entered into a pair of R&D collaboration and option deals for early-stage cancer candidates that it claims could offer both a first-in-class opportunity with a peptide-drug conjuga

Chinook Therapeutics, Inc. is developing a pair of drugs – an oral tablet and a monoclonal antibody – for IgA nephropathy, with potentially pivotal data expected for the oral drug in 2023. The Vancou

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Biolojic To Use Computational Platform